Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736506 | 0.95 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1MBTD1SLC18A3HTR6 | |
| SCHEMBL735454 | 0.93 | SLC18A3 (0.37) | L3MBTL3L3MBTL1SLC18A3HTR6 | |
| SCHEMBL2003992 | 0.93 | SLC18A3 (0.37) | L3MBTL3L3MBTL1SLC18A3HTR6 | |
| SCHEMBL736159 | 0.93 | — | — | |
| SCHEMBL736888 | 0.88 | — | — | |
| SCHEMBL17100712 | 0.84 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1SLC18A3HTR6 | |
| SCHEMBL735446 | 0.83 | SLC18A3 (0.35) | L3MBTL3L3MBTL1SLC18A3HTR6 | |
| SCHEMBL16538765 | 0.83 | ALDH1A1 (0.42) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL2007966 | 0.81 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1SLC18A3HTR6 | |
| SCHEMBL2006246 | 0.81 | SLC18A3 (0.38) | SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370110-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| CN-117940120-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| EP-4175642-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115843251-A | Compounds, compositions and methods | 戴纳立制药公司 | 2023-03-24 | — | — | CN | claimed |
| WO-2023288039-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | claimed |
| CN-107406414-B | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2022-04-19 | — | — | CN | claimed |
| WO-2022006433-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-01-06 | — | — | WO | claimed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | claimed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | claimed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | claimed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | claimed |
| EP-3242872-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | claimed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | claimed |
| WO-2016112284-A1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | L3MBTL3 1925/4885L3MBTL1 1773/4885MBTD1 3620/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | L3MBTL3 232/4885L3MBTL1 1306/4885MBTD1 1217/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | L3MBTL3 1925/4885L3MBTL1 1773/4885MBTD1 3620/4885 |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | L3MBTL3 258/4885L3MBTL1 1391/4885MBTD1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.